CN102600108A - Flurbiprofen sustained release capsules and preparation method thereof - Google Patents
Flurbiprofen sustained release capsules and preparation method thereof Download PDFInfo
- Publication number
- CN102600108A CN102600108A CN2012100209893A CN201210020989A CN102600108A CN 102600108 A CN102600108 A CN 102600108A CN 2012100209893 A CN2012100209893 A CN 2012100209893A CN 201210020989 A CN201210020989 A CN 201210020989A CN 102600108 A CN102600108 A CN 102600108A
- Authority
- CN
- China
- Prior art keywords
- flurbiprofen
- sustained release
- slow
- release
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 38
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 229960002390 flurbiprofen Drugs 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 238000013268 sustained release Methods 0.000 title claims abstract description 19
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000010410 layer Substances 0.000 claims abstract description 8
- 239000011247 coating layer Substances 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 6
- 238000005563 spheronization Methods 0.000 claims abstract description 4
- 239000006187 pill Substances 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 23
- 238000000576 coating method Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 230000005070 ripening Effects 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000004014 plasticizer Substances 0.000 claims description 6
- 239000003361 porogen Substances 0.000 claims description 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 239000007779 soft material Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- -1 hydroxypropyl Chemical group 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000000113 methacrylic resin Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000001069 triethyl citrate Substances 0.000 claims description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000013769 triethyl citrate Nutrition 0.000 claims description 3
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 25
- 229940079593 drug Drugs 0.000 abstract description 13
- 239000002245 particle Substances 0.000 abstract description 7
- 239000008188 pellet Substances 0.000 abstract description 5
- 208000002193 Pain Diseases 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000007547 defect Effects 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 239000007939 sustained release tablet Substances 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000003826 tablet Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000001476 alcoholic effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000011812 mixed powder Substances 0.000 description 3
- 238000000643 oven drying Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 1
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- 101001018100 Homo sapiens Lysozyme C Proteins 0.000 description 1
- 102100033468 Lysozyme C Human genes 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038357 Renal amyloidosis Diseases 0.000 description 1
- 208000009921 Rheumatoid Nodule Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 108010017796 epoxidase Proteins 0.000 description 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
- 201000007891 familial visceral amyloidosis Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- DLWSRGHNJVLJAH-UHFFFAOYSA-N nitroflurbiprofen Chemical compound FC1=CC(C(C(=O)OCCCCO[N+]([O-])=O)C)=CC=C1C1=CC=CC=C1 DLWSRGHNJVLJAH-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
- 229960000488 tizanidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses flurbiprofen sustained release capsules and a preparation method of the flurbiprofen sustained release capsules. The flurbiprofen sustained release capsules consist of sustained release pellets and hollow capsules; and each sustained release pellet consists of the following raw materials by weight: 75-97% of drug-containing core and 3-25% of a sustained release coating layer. The flurbiprofen sustained release capsules consist of hundreds of sustained release pellets with uniform particle sizes, and errors or defects appearing in the preparation method of some pellets are unlikely to have serious influence on drug release of the whole preparation, so that the flurbiprofen sustained release capsules are safer than that of the sustained release tablets, have little irritation to gastrointestinal tract, have more stable plasma concentration and higher bioavailability and can continuously release drug to relieve inflammation and pain for 24 hours by administration once in a day. The preparation method provided by the invention adopts a extrusion-spheronization method to prepare the drug-containing cores and adopts a fluidized bed to wrap the sustained release coat layers; and the flurbiprofen sustained release capsules have simple process and are easy for industrial production.
Description
Technical field
The present invention relates to the technical field of flurbiprofen slow releasing preparation, relate in particular to a kind of flurbiprofen slow releasing capsule and preparation method thereof.It belongs to a kind of non-steroidal anti-inflammatory analgesics slow releasing preparation.
Background technology
(rheumatoidarthritis is the not clear as yet chronic heterogeneous systemic disease of a kind of cause of disease RA) to rheumatoid arthritis, belongs to autoimmune disease.Maybe be relevant with multiple factors such as infection, heredity and disorders of immune mechanism.Mainly show as symmetric multi-joint chronic nonspecific inflammation on every side; Can be with abarticular systematicness infringement; For example cause multiple pathological changes such as subcutaneous rheumatoid nodules, pericarditis, myocarditis, pulmonary fibrosis, pleuritis, splenomegaly, renal amyloidosis, peripheral neuritis, arteritis; Sometimes also possibly invade eyes, scleritis, iritis take place.The prevalence of RA increases with advancing age and gradually, and the research of most colonies shows that prevalence is the highest among old peoples' (over-65s or more than 70 years old).In elderly population, the prevalence of those schoolings junior RA is the highest, and the women is a little more than the male.China never has nationwide definite data about the arthritic epidemic data of rheumatoid property, has only the epidemic data of some areas.According to relevant report, the prevalence of China's rheumatoid arthritis is approximately 0.32%-0.36%.
The nonsteroidal anti-inflammatory immune substance is a line medication of treatment rheumatoid arthritis disease, and this type medicine has pain relieving and antiphlogistic characteristic, thereby can alleviate arthralgia and swelling, but can not change disease process or stop destruction of joint, therefore can not use separately.This type of medicine gets final product onset in the general a few days, expresses one's gratification again and does medication.Slowly doing medication as yet not during onset, using that NSAIIDs is beneficial to patient's function of joint and quality of life improves as early as possible.
Flurbiprofen (Flurbiprofen) is an aryl propionic non-steroid antiphlogistic, is one of outstanding kind in the non-steroidal anti-inflammatory analgesic, is used to treat rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, wound pain and other pain clinically.This medicine is oral effectively, better tolerance, and life-time service neither promotes also not suppress self metabolism.Thereby flurbiprofen plays the effect of anti-inflammatory analgesic through the activity that suppresses the prostaglandin synthetase epoxidase; In molecular structure, introduced a fluorine atom; The special performance that is caused by fluorine atom acts on it in similar medicine stronger; Therapeutic dose is little, thereby possesses powerful antiinflammatory, pain relieving and the function of bringing down a fever, and side effect is minimized.These article reach the clinical observation in 4 years through 21 treatment 1396 patients of unit of Britain, do not see obvious toxic and side effects.
The about 0.038mg/ml of the dissolubility of flurbiprofen in water is low dissolving high osmosis (ClassII class) medicine, and dissolubility increases under alkali condition.Half-life is about 6 hours, absorbs basically fully after oral, and the influence of unable to take food thing, the blood plasma combination rate is about 90%, and its biopharmaceutics characteristic shows the suitable slow releasing preparation that is developed as.
Controlled release flurbiprofen and muscle relaxant composition of medicine (patent No.: EP2074990, US20090175938; SANOVEL ILAC SANAYIVE TICARET); Describe be once a day, flurbiprofen and the muscle relaxant tizanidine controlled release double-layer tablet and the preparation technology thereof of release in 24 hours; Medicine nand function property adjuvant and slow release material mixing are processed granule, be pressed into double-layer tablet, belong to matrix sustained release tablet; Slow releasing tablet partial breakage and defective when producing can cause the prominent of total formulation to release generation, so safety is relatively poor.
Flurbiprofen slow releasing capsule (trade name: Froben SR) go on the market in European Union's approval in calendar year 2001 by the production of Abbott company; Listing is produced at present domestic existing flurbiprofen slow releasing tablet approval; Temporarily no flurbiprofen slow releasing capsule produces listing and registration is declared, and the flurbiprofen slow releasing capsule that develop once a day, 24 hours discharges has the good clinical application advantage.
Summary of the invention
The objective of the invention is to overcome the shortcoming and defect of prior art, a kind of have persistent, medicining times is few, blood drug level is steady, safety is higher flurbiprofen slow releasing capsule are provided.Based on this, the present invention also provides a kind of method for preparing of flurbiprofen slow releasing capsule.
The diameter that micropill is made up of medicine and adjuvant is about the miniature spherical entity of 1mm; According to different therapeutic doses and requirement; Micropill is that the medicine with dose is dispersed in 1,100 miniature spherical compartments; Error or the defective of indivedual micropills in preparation is unlikely to the drug release behavior of whole preparation is affected greatly, and significantly reduced the prominent generation of releasing of medicine.There is bigger contact surface the oral back of micropill with the gastrointestinal tract surface, and absorption is good and little to partial zest, and simultaneously, micropill is different with tablet, and the former does not receive the gastric emptying factor affecting basically, so the infiltration rate of medicine is even, individual bioavailability difference is also little.Micropill has advantages such as particle diameter is even, good fluidity, difficult crushing; Particularly the fine pellet core surface coatings, to process location, sustained-release preparation, technology simple; Can avoid coatings such as other solid preparations such as tablet inhomogeneous, may cause that the medicine sky is released, the risk of pulse.By the slow releasing capsule that the micropill of different pharmaceutical is formed, can increase advantages such as stability of drug, raising curative effect, reduction poisonous side effect of medicine.
For solving above technical problem, technical scheme of the present invention is:
A kind of slow releasing capsule of flurbiprofen is made up of slow-release micro-pill and Capsules two parts, counts by weight percentage, and said slow-release micro-pill is made up of 75～97% the sustained release coating layer that contains pill core and 3～25%, wherein:
Containing pill core comprises: 40～65% flurbiprofen and 22～56.5% excipient, 3～8% binding agent and 0.5～5% solubilizing agent, more than the percentage by weight of each component all to contain the total weight of pill core;
The sustained release coating layer comprises: 3～25% slow-release material, 15～80% antiplastering aid, 10～30% plasticizer and 3～30% porogen; More than in each component; The percentage by weight of slow-release material to be containing the total weight of pill core, and the percentage by weight of antiplastering aid, plasticizer and porogen is all with the total weight of slow-release material.
Preferably, said excipient is one or more the mixture in lactose, microcrystalline Cellulose, mannitol, starch, dextrin, the sucrose.
Preferably, said binding agent is one or more the mixture in polyvinylpyrrolidone, hydroxypropyl emthylcellulose, the carboxymethyl cellulose.
Preferably, said solubilizing agent is one or more the mixture in sodium lauryl sulphate, tween, the Polyethylene Glycol.
Said slow-release material is methacrylic resin polymer or ethyl cellulose; Preferably; The methacrylic resin polymer is one or more the mixture among Eudragit NE30D, Eudragit RS30D, Eudragit RL30D, Eudragit RS, the Eudragit RL, and ethyl cellulose is Surelease or Aquacoat.
Preferably, said antiplastering aid is one or more the mixture in Pulvis Talci, magnesium stearate, silicon dioxide, the titanium dioxide.
Preferably, said plasticizer is one or more the mixture in diethyl phthalate, dibutyl phthalate, triethyl citrate, ATBC, dibutyl sebacate, the glycerol.
Preferably, said porogen is one or more the mixture in lactose, polyvinylpyrrolidone, polyethylene glycols, the hydroxypropyl emthylcellulose.
The release in vitro degree of the flurbiprofen slow releasing capsule that above-mentioned optimizing prescriptions makes is: 2 hours 10～25%, and 4 hours 20～45%, 8 hours 40～70%, 12 hours 60～90%, 24 hours＞85%.
Preferably, described flurbiprofen slow releasing capsule adopts extrudes the spheronization preparation, comprises the steps:
(1) contain the preparation of pill core: with flurbiprofen and excipient mix homogeneously, mixing purified water (or ethanol) solution that adds solubilizing agent and binding agent is processed soft material, and employing is extruded spheronization and processed 20～40 purposes and contain pill core, drying.
(2) bag slow release layer: will contain pill core and place fluid bed, bag sustained release coating liquid makes slow-release micro-pill.
(3) ripening: slow-release micro-pill was placed 35 ℃～55 ℃ baking oven matured 8～24 hours.
(4) process capsule: the slow-release micro-pill after the ripening is filled in the Capsules.
Device parameter in the coating process, intake 20～30HZ, EAT are 35～55 ℃, and temperature of charge is 25～45 ℃, and atomizing pressure is 1.0bar, and hydrojet speed is 2～4g/min.
Thermostatic drying chamber is adopted in ripening, and temperature is controlled at 30 ℃～50 ℃, and the curing time is 8～24 hours.
The flurbiprofen slow releasing capsule that the present invention makes is made up of 1,100 uniform slow-release micro-pill of particle diameter; Error or the defective of indivedual micropills in preparation is unlikely drug release behavior to total formulation and produces and have a strong impact on; Therefore more safer than slow releasing tablet, littler to the gastrointestinal zest, blood drug level is more steady; Bioavailability is higher, and taking 1 time in one day can lasting release in 24 hours.
Method for preparing employing of the present invention is extruded round as a ball method preparation and is contained pill core, and particle diameter is 20～40 orders, adopts fluid bed bag sustained-release coating layer, and technology is simple, is easy to industrialized great production.
Description of drawings
Fig. 1～Fig. 3: the flurbiprofen slow releasing capsule that makes for the embodiment of the invention one～embodiment three releasing curve diagram of 2,4,8,12,24 hours in external multiple release medium.
The specific embodiment
In order to make those skilled in the art understand technical scheme of the present invention better, the present invention is done further detailed description below in conjunction with specific embodiment.
Embodiment one:
1, contain the preparation of pill core:
Preparation technology: with the method mix homogeneously that flurbiprofen and microcrystalline Cellulose adopt equivalent to increase progressively, sodium lauryl sulphate is added to that dissolving is mixed with the sodium lauryl sulphate alcoholic solution in 35% alcoholic solution, and above-mentioned mixed powder is processed soft material; Round as a ball machine-processed micropill is extruded in employing; The sieve plate particle diameter is 0.8mm, and 60 ℃ of oven dryings sieve; Choose 20～40 orders and contain pill core, carry out coating.
2, bag slow release layer:
The Sulisi of recipe quantity is joined in the purified water, it is fully disperseed, stir 45min, will contain pill core and place fluid bed, adjust each technological parameter, guarantee fluidized state, coating increases weight to 12%.
The technological parameter of fluid bed: intake: 20～30HZ, EAT: 45～55 ℃, temperature of charge: 40～45 ℃, atomizing pressure: 1.0bar, hydrojet speed: 2～4g/min.
3, ripening: 50 ℃ of baking oven matured 12 hours.
4, make capsule: capsule is filled, and promptly gets.
To make sample; Adopt pH1.2 hydrochloric acid solution, pH4.5 phosphate buffer, pH6.8 phosphate buffer, pH7.2 phosphate buffer and water as release medium respectively; With changeing the basket method, with 100 rev/mins, respectively sampling in 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours; Measure trap, calculating cumulative release degree with the UV method in the 246nm wavelength.The result is following:
Embodiment two:
1, contain the preparation of pill core:
Preparation technology: with the method mix homogeneously that flurbiprofen and lactose, microcrystalline Cellulose adopt equivalent to increase progressively, tween is added in 35% alcoholic solution, and above-mentioned mixed powder is processed soft material; Round as a ball machine-processed micropill is extruded in employing; The sieve plate particle diameter is 0.8mm, and 60 ℃ of oven dryings sieve; Choose 20～40 orders and contain pill core, carry out coating.
2, bag slow release layer:
With the Pulvis Talci of recipe quantity, join and stir 45min in the purified water, add the strange NE30D aqueous dispersion of You Te it is fully disperseed, continue to stir 45min, subsequent use.To contain pill core and place fluid bed, and regulate each technological parameter, and guarantee fluidized state, coating increases weight to 4%.
The technological parameter of fluid bed: intake: 20～30HZ, EAT: 35～45 ℃, temperature of charge: 30～35 ℃, atomizing pressure: 1.0bar, hydrojet speed: 2～4g/min.
3, ripening: 40 ℃ of baking oven matured 24 hours.
4, make capsule: capsule is filled, and promptly gets.
To make sample; Adopt pH1.2 hydrochloric acid solution, pH4.5 phosphate buffer, pH6.8 phosphate buffer, pH7.2 phosphate buffer and water as release medium respectively; With changeing the basket method, with 100 rev/mins, respectively sampling in 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours; Measure trap, calculating cumulative release degree with the UV method in the 246nm wavelength.The result is following:
Embodiment three:
1, contain the preparation of pill core:
Preparation technology: with the method mix homogeneously that flurbiprofen and microcrystalline Cellulose, mannitol adopt equivalent to increase progressively, PVP-K30 and tween are added in 35% alcoholic solution, and above-mentioned mixed powder is processed soft material; Round as a ball machine-processed micropill is extruded in employing; The sieve plate particle diameter is 0.8mm, and 60 ℃ of oven dryings sieve; Choose 20～40 orders and contain pill core, carry out coating.
2, bag slow release layer:
The Pulvis Talci of recipe quantity joined stir 45min in the purified water, add triethyl citrate, the strange RS30D of You Te and RL30D aqueous dispersion it is fully disperseed, continue to stir 45min, subsequent use.To contain pill core and place fluid bed, and regulate each technological parameter, and guarantee fluidized state, coating increases weight to 8%.
The technological parameter of fluid bed: intake: 20～30HZ, EAT: 35～45 ℃, temperature of charge: 30～35 ℃, atomizing pressure: 1.0bar, hydrojet speed: 2～4g/min.
3, ripening: 40 ℃ of baking oven matured 24 hours.
4, make capsule: capsule is filled, and promptly gets.
To make sample; Adopt pH1.2 hydrochloric acid solution, pH4.5 phosphate buffer, pH6.8 phosphate buffer, pH7.2 phosphate buffer and water as release medium respectively; With changeing the basket method, with 100 rev/mins, respectively sampling in 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours; Measure trap, calculating cumulative release degree with the UV method in the 246nm wavelength.The result is following:
Compliance test result
External release test:
Get slow releasing capsule that embodiment one, two, three makes as sample; Pressing the UV method detects; Adopt pH1.2 hydrochloric acid solution, pH4.5 phosphate buffer, pH6.8 phosphate buffer, pH7.2 phosphate buffer and water as release medium, carried out the release in vitro degree respectively at 2,4,8,12,24 hours and measure, detect among data and Fig. 1～Fig. 3 and can find out by the release degree; 3 lot sample article discharge in 24 hours evenly in multiple release medium; All meet one-level release dynamic process, be illustrated in the external slow release characteristic that has, the further research of release in the body.
More than the present invention has been carried out detailed introduction, use concrete example in the literary composition principle of the present invention and embodiment set forth, the explanation of above embodiment just is used for helping to understand method of the present invention and core concept thereof.Should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the principle of the invention, can also carry out some improvement and modification to the present invention, these improvement and modification also fall in the protection domain of claim of the present invention.
Claims (4)
1. the slow releasing capsule of a flurbiprofen; It is characterized in that; Form by slow-release micro-pill and Capsules two parts; Count by weight percentage, said slow-release micro-pill by 75～97% contain pill core, 3～25% sustained release coating layer is formed, wherein; Contain pill core and comprise flurbiprofen 40～65%, excipient 22～56.5%, binding agent 3～8% and solubilizing agent 0.5～5%, the sustained release coating layer comprises slow-release material 3～25%, antiplastering aid 15～80%, plasticizer 10～30% and porogen 3～30%.
More than in each component, the percentage by weight of excipient, binding agent, solubilizing agent and slow-release material to be containing the total weight of pill core, the percentage by weight of antiplastering aid, plasticizer and porogen is all with the total weight of slow-release material.
2. flurbiprofen slow releasing capsule according to claim 1 is characterized in that,
Said excipient is one or more the mixture in lactose, microcrystalline Cellulose, mannitol, starch, dextrin, the sucrose.
Said binding agent is one or more the mixture in polyvinylpyrrolidone, hydroxypropyl emthylcellulose, the carboxymethyl cellulose.
Said solubilizing agent is one or more the mixture in sodium lauryl sulphate, tween, the Polyethylene Glycol.
Said slow-release material is one or more a mixture of methacrylic resin polymer or ethyl cellulose.
Said antiplastering aid is one or more the mixture in Pulvis Talci, magnesium stearate, silicon dioxide, the titanium dioxide.
Said plasticizer is one or more the mixture in diethyl phthalate, dibutyl phthalate, triethyl citrate, ATBC, dibutyl sebacate, the glycerol.
Said porogen is one or more the mixture in lactose, polyvinylpyrrolidone, polyethylene glycols, the hydroxypropyl emthylcellulose.
3. flurbiprofen slow releasing capsule according to claim 1 is characterized in that, the release in vitro degree is: 2 hours 10～25%, and 4 hours 20～45%, 8 hours 40～70%, 12 hours 60～90%, 24 hours＞85%.
4. the method for preparing of flurbiprofen slow releasing capsule according to claim 1 comprises the steps:
(1) contain the preparation of pill core: with flurbiprofen and excipient mix homogeneously, mixing purified water (or ethanol) solution that adds solubilizing agent and binding agent is processed soft material, and employing is extruded spheronization and processed 20～40 purposes and contain pill core, drying.
(2) bag slow release layer: will contain pill core and place fluid bed, bag sustained release coating liquid makes slow-release micro-pill.
(3) ripening: slow-release micro-pill was placed 35 ℃～55 ℃ baking oven matured 8～24 hours.
(4) process capsule: the slow-release micro-pill after the ripening is filled in the Capsules.
Device parameter in the coating process, intake 20～30HZ, EAT are 35～55 ℃, and temperature of charge is 25～45 ℃, and atomizing pressure is 1.0bar, and hydrojet speed is 2～4g/min.
Thermostatic drying chamber is adopted in ripening, and temperature is controlled at 30 ℃～50 ℃, and the curing time is 8～24 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100209893A CN102600108A (en) | 2012-01-17 | 2012-01-17 | Flurbiprofen sustained release capsules and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100209893A CN102600108A (en) | 2012-01-17 | 2012-01-17 | Flurbiprofen sustained release capsules and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102600108A true CN102600108A (en) | 2012-07-25 |
Family
ID=46518138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100209893A Pending CN102600108A (en) | 2012-01-17 | 2012-01-17 | Flurbiprofen sustained release capsules and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102600108A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113350304A (en) * | 2021-07-15 | 2021-09-07 | 上海博悦生物科技有限公司 | Non-steroidal anti-inflammatory sustained release preparation and preparation method thereof |
| CN114432257A (en) * | 2022-01-24 | 2022-05-06 | 南京一诺医药科技有限公司 | Difluofen sustained-release tablet and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1277550A (en) * | 1997-09-11 | 2000-12-20 | 尼科梅德丹麦有限公司 | Compound composition for improved release of non-steroidal anti-inflammatory drugs (NSAIDs) |
| CN1628648A (en) * | 2004-08-26 | 2005-06-22 | 复旦大学 | Loxoprofen Sodium Sustained Release Preparation |
| CN101453993A (en) * | 2006-04-03 | 2009-06-10 | 伊萨·奥迪迪 | Controlled release delivery device containing organosol coating |
| CN102228441A (en) * | 2011-06-23 | 2011-11-02 | 湖北丝宝药业有限公司 | Dexibuprofen sustained-release pellet and preparation method thereof |
-
2012
- 2012-01-17 CN CN2012100209893A patent/CN102600108A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1277550A (en) * | 1997-09-11 | 2000-12-20 | 尼科梅德丹麦有限公司 | Compound composition for improved release of non-steroidal anti-inflammatory drugs (NSAIDs) |
| CN1628648A (en) * | 2004-08-26 | 2005-06-22 | 复旦大学 | Loxoprofen Sodium Sustained Release Preparation |
| CN101453993A (en) * | 2006-04-03 | 2009-06-10 | 伊萨·奥迪迪 | Controlled release delivery device containing organosol coating |
| CN102228441A (en) * | 2011-06-23 | 2011-11-02 | 湖北丝宝药业有限公司 | Dexibuprofen sustained-release pellet and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| XIAOMEI WANG等: "In vitro release and pharmacokinetics of flurbiprofen sustained-release capsules containing coated pellets", 《ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113350304A (en) * | 2021-07-15 | 2021-09-07 | 上海博悦生物科技有限公司 | Non-steroidal anti-inflammatory sustained release preparation and preparation method thereof |
| CN114432257A (en) * | 2022-01-24 | 2022-05-06 | 南京一诺医药科技有限公司 | Difluofen sustained-release tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103142552A (en) | Lovastatin enteric coated sustained-release pellet capsule and preparation method thereof | |
| KR20100059912A (en) | Pharmaceutical combination of aliskiren and valsartan | |
| CN105338970B (en) | Drug capsule combination formulation containing tadalafil and tamsulosin | |
| CN108348472A (en) | Optimized Tablets Containing High Dose Mesalamine | |
| WO2014040548A1 (en) | Metoprolol sustained-release drug and preparation method therefor | |
| CN103520129A (en) | Montelukast sodium pulse release preparation | |
| CN105832671A (en) | Dry suspension for controlled-release of medicine and preparation method of dry suspension | |
| CN115581686B (en) | Preparation method of pregabalin capsule and pregabalin capsule | |
| WO2013189305A1 (en) | Valsartan-amlodipine compound solid preparation and preparation method therefor | |
| CN102600451B (en) | Felodipine ramipril compound sustained-release preparation and preparation method thereof | |
| CN103417496A (en) | Method for preparing metformin hydrochloride controlled-release pellet preparation | |
| CN106176652A (en) | A kind of diabecron sustained-release tablet and preparation method thereof | |
| CN102600108A (en) | Flurbiprofen sustained release capsules and preparation method thereof | |
| CN101411702B (en) | Nefopam hydrochloride naproxen sodium compound sustained-release preparation and preparation method thereof | |
| CN100488515C (en) | Ground erythromycin enteric micropill and its preparation method | |
| CN105412904A (en) | Linaclotide enteric controlled-release pellet capsule preparation and preparing method and application thereof | |
| CN1248693C (en) | Sustained release formulation of glucosamine salt, its preparation and usage | |
| US20240139110A1 (en) | Sleep-regulating tablet allowing release by stages and preparation method thereof | |
| CN102429873A (en) | Desvenlafaxine sustained-release pellet and preparation method thereof | |
| CN104224728A (en) | Esomeprazole enteric-coated pellets and preparation method for same | |
| CN110575443A (en) | Doxofylline sustained release tablet and preparation method thereof | |
| CN103446062A (en) | Preparing method of compound metformin hydrochloride and pioglitazone hydrochloride slow-release micro-pellet preparation | |
| CN105663063B (en) | Compound pellet tablet of diammonium glycyrrhizinate and Entecavir and preparation method thereof | |
| CN102429872B (en) | Zileuton-containing membrane-controlled slow release pellets and preparation method thereof | |
| WO2015196956A1 (en) | Metoprolol sustained-release composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120725 |
|
| WD01 | Invention patent application deemed withdrawn after publication |